Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy

OBJECTIVE: To assess the validity of pre- and posttreatment computed tomography (CT)-based radiomics signatures and delta radiomics signatures for predicting progression-free survival (PFS) in stage III-IV non-small-cell lung cancer (NSCLC) patients after immune checkpoint inhibitor (ICI) therapy. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Dong, Xu, Fangyi, Zhu, Wenchao, Pu, Cailing, Huang, Shaoyu, Lou, Kaihua, Wu, Yan, Huang, Dingpin, He, Cong, Hu, Hongjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583844/
https://www.ncbi.nlm.nih.gov/pubmed/36276082
http://dx.doi.org/10.3389/fonc.2022.990608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583844/
https://www.ncbi.nlm.nih.gov/pubmed/36276082
http://dx.doi.org/10.3389/fonc.2022.990608

Ejemplares similares